Dr. Malcolm Moore New drug development

Dr. Moore is the Director of the Bras Family New Drug Development Program at Princess Margaret Hospital. His major interest over the past 10 years has been innovative drug development for cancer therapy, and he has been a principal investigator for many phase I, II and III studies in gastrointestinal and genitourinary cancer. He has been instrumental in the development of several agents that have subsequently been approved for clinical usage, including both gemcitabine and erlotinib in pancreatic cancer.

Dr. Moore is a member of the American Society of Clinical Oncology Program Committee, an executive member of the North American Gastrointestinal (GI) Intergroup, and chair of the National Cancer Institute of Canada GI committee. He has authored over 130 peer-reviewed publications and has given over 150 invited lectures worldwide.

• Ho Chair in Prostate Cancer Research, Princess Margaret Hospital
• Chair of the National Cancer Institute of Canada GI Cancer Disease Site
• Professor, Department of Medicine and Pharmacology, University of Toronto